Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. I) Protective activity against experimental neurogenic gastric ulcers and other pharmacologic properties.
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D001833:Body Temperature Regulation / Q000187:drug effects; D003080:Cold Temperature; D005769:Gastrointestinal Motility / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007103:Immobilization; D008026:Ligation; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D011708:Pylorus; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D013270:Stomach / Q000187:drug effects; D013276:Stomach Ulcer / Q000209:etiology / Q000517:prevention & control*; D013312:Stress, Physiological / Q000150:complications
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D010276:Parasympatholytics; D011725:Pyridines